- call +1-201-465-4211
- email sales@marketsandresearch.biz
- Call +1-201-465-4211
- Email: sales@marketsandresearch.biz
The Opioid-Induced Constipation market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest study, due to COVID-19 pandemic, the global Opioid-Induced Constipation market size is estimated to be worth US$ 2604.3 million in 2021 and is forecast to a readjusted size of USD 3520.9 million by 2028 with a CAGR of 4.4% during review period. Hospital accounting for % of the Opioid-Induced Constipation global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Methylnaltrexone Bromide segment is altered to a % CAGR between 2022 and 2028.
Global key manufacturers of Opioid-Induced Constipation include Takeda Pharmaceuticals, Bayer, Sanofi, Mallinckrodt, and Salix (Bausch Health), etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Opioid-Induced Constipation market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Methylnaltrexone Bromide
Lubiprostone
Naloxegol
Others
Market segment by Application can be divided into
Hospital
Pharmacy
Other
The key market players for global Opioid-Induced Constipation market are listed below:
Takeda Pharmaceuticals
Bayer
Sanofi
Mallinckrodt
Salix (Bausch Health)
AstraZeneca
Progenics Pharmaceuticals
Purdue Pharm
Nektar Therapeutics
Daiichi Sankyo
Prestige
GSK
Shionogi
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Opioid-Induced Constipation product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Opioid-Induced Constipation, with price, sales, revenue and global market share of Opioid-Induced Constipation from 2019 to 2022.
Chapter 3, the Opioid-Induced Constipation competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Opioid-Induced Constipation breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and Opioid-Induced Constipation market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Opioid-Induced Constipation.
Chapter 13, 14, and 15, to describe Opioid-Induced Constipation sales channel, distributors, customers, research findings and conclusion, appendix and data source.
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
1 Market Overview
1.1 Opioid-Induced Constipation Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Opioid-Induced Constipation Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 Methylnaltrexone Bromide
1.2.3 Lubiprostone
1.2.4 Naloxegol
1.2.5 Others
1.3 Market Analysis by Application
1.3.1 Overview: Global Opioid-Induced Constipation Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 Hospital
1.3.3 Pharmacy
1.3.4 Other
1.4 Global Opioid-Induced Constipation Market Size & Forecast
1.4.1 Global Opioid-Induced Constipation Sales in Value (2017 & 2021 & 2028)
1.4.2 Global Opioid-Induced Constipation Sales in Volume (2017-2028)
1.4.3 Global Opioid-Induced Constipation Price (2017-2028)
1.5 Global Opioid-Induced Constipation Production Capacity Analysis
1.5.1 Global Opioid-Induced Constipation Total Production Capacity (2017-2028)
1.5.2 Global Opioid-Induced Constipation Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Opioid-Induced Constipation Market Drivers
1.6.2 Opioid-Induced Constipation Market Restraints
1.6.3 Opioid-Induced Constipation Trends Analysis
2 Manufacturers Profiles
2.1 Takeda Pharmaceuticals
2.1.1 Takeda Pharmaceuticals Details
2.1.2 Takeda Pharmaceuticals Major Business
2.1.3 Takeda Pharmaceuticals Opioid-Induced Constipation Product and Services
2.1.4 Takeda Pharmaceuticals Opioid-Induced Constipation Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2 Bayer
2.2.1 Bayer Details
2.2.2 Bayer Major Business
2.2.3 Bayer Opioid-Induced Constipation Product and Services
2.2.4 Bayer Opioid-Induced Constipation Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3 Sanofi
2.3.1 Sanofi Details
2.3.2 Sanofi Major Business
2.3.3 Sanofi Opioid-Induced Constipation Product and Services
2.3.4 Sanofi Opioid-Induced Constipation Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4 Mallinckrodt
2.4.1 Mallinckrodt Details
2.4.2 Mallinckrodt Major Business
2.4.3 Mallinckrodt Opioid-Induced Constipation Product and Services
2.4.4 Mallinckrodt Opioid-Induced Constipation Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5 Salix (Bausch Health)
2.5.1 Salix (Bausch Health) Details
2.5.2 Salix (Bausch Health) Major Business
2.5.3 Salix (Bausch Health) Opioid-Induced Constipation Product and Services
2.5.4 Salix (Bausch Health) Opioid-Induced Constipation Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6 AstraZeneca
2.6.1 AstraZeneca Details
2.6.2 AstraZeneca Major Business
2.6.3 AstraZeneca Opioid-Induced Constipation Product and Services
2.6.4 AstraZeneca Opioid-Induced Constipation Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7 Progenics Pharmaceuticals
2.7.1 Progenics Pharmaceuticals Details
2.7.2 Progenics Pharmaceuticals Major Business
2.7.3 Progenics Pharmaceuticals Opioid-Induced Constipation Product and Services
2.7.4 Progenics Pharmaceuticals Opioid-Induced Constipation Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8 Purdue Pharm
2.8.1 Purdue Pharm Details
2.8.2 Purdue Pharm Major Business
2.8.3 Purdue Pharm Opioid-Induced Constipation Product and Services
2.8.4 Purdue Pharm Opioid-Induced Constipation Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9 Nektar Therapeutics
2.9.1 Nektar Therapeutics Details
2.9.2 Nektar Therapeutics Major Business
2.9.3 Nektar Therapeutics Opioid-Induced Constipation Product and Services
2.9.4 Nektar Therapeutics Opioid-Induced Constipation Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.10 Daiichi Sankyo
2.10.1 Daiichi Sankyo Details
2.10.2 Daiichi Sankyo Major Business
2.10.3 Daiichi Sankyo Opioid-Induced Constipation Product and Services
2.10.4 Daiichi Sankyo Opioid-Induced Constipation Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.11 Prestige
2.11.1 Prestige Details
2.11.2 Prestige Major Business
2.11.3 Prestige Opioid-Induced Constipation Product and Services
2.11.4 Prestige Opioid-Induced Constipation Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.12 GSK
2.12.1 GSK Details
2.12.2 GSK Major Business
2.12.3 GSK Opioid-Induced Constipation Product and Services
2.12.4 GSK Opioid-Induced Constipation Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.13 Shionogi
2.13.1 Shionogi Details
2.13.2 Shionogi Major Business
2.13.3 Shionogi Opioid-Induced Constipation Product and Services
2.13.4 Shionogi Opioid-Induced Constipation Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 Opioid-Induced Constipation Breakdown Data by Manufacturer
3.1 Global Opioid-Induced Constipation Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global Opioid-Induced Constipation Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in Opioid-Induced Constipation
3.4 Market Concentration Rate
3.4.1 Top 3 Opioid-Induced Constipation Manufacturer Market Share in 2021
3.4.2 Top 6 Opioid-Induced Constipation Manufacturer Market Share in 2021
3.5 Global Opioid-Induced Constipation Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and Opioid-Induced Constipation Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Opioid-Induced Constipation Market Size by Region
4.1.1 Global Opioid-Induced Constipation Sales in Volume by Region (2017-2028)
4.1.2 Global Opioid-Induced Constipation Revenue by Region (2017-2028)
4.2 North America Opioid-Induced Constipation Revenue (2017-2028)
4.3 Europe Opioid-Induced Constipation Revenue (2017-2028)
4.4 Asia-Pacific Opioid-Induced Constipation Revenue (2017-2028)
4.5 South America Opioid-Induced Constipation Revenue (2017-2028)
4.6 Middle East and Africa Opioid-Induced Constipation Revenue (2017-2028)
5 Market Segment by Type
5.1 Global Opioid-Induced Constipation Sales in Volume by Type (2017-2028)
5.2 Global Opioid-Induced Constipation Revenue by Type (2017-2028)
5.3 Global Opioid-Induced Constipation Price by Type (2017-2028)
6 Market Segment by Application
6.1 Global Opioid-Induced Constipation Sales in Volume by Application (2017-2028)
6.2 Global Opioid-Induced Constipation Revenue by Application (2017-2028)
6.3 Global Opioid-Induced Constipation Price by Application (2017-2028)
7 North America by Country, by Type, and by Application
7.1 North America Opioid-Induced Constipation Sales by Type (2017-2028)
7.2 North America Opioid-Induced Constipation Sales by Application (2017-2028)
7.3 North America Opioid-Induced Constipation Market Size by Country
7.3.1 North America Opioid-Induced Constipation Sales in Volume by Country (2017-2028)
7.3.2 North America Opioid-Induced Constipation Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 Europe by Country, by Type, and by Application
8.1 Europe Opioid-Induced Constipation Sales by Type (2017-2028)
8.2 Europe Opioid-Induced Constipation Sales by Application (2017-2028)
8.3 Europe Opioid-Induced Constipation Market Size by Country
8.3.1 Europe Opioid-Induced Constipation Sales in Volume by Country (2017-2028)
8.3.2 Europe Opioid-Induced Constipation Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 Asia-Pacific by Region, by Type, and by Application
9.1 Asia-Pacific Opioid-Induced Constipation Sales by Type (2017-2028)
9.2 Asia-Pacific Opioid-Induced Constipation Sales by Application (2017-2028)
9.3 Asia-Pacific Opioid-Induced Constipation Market Size by Region
9.3.1 Asia-Pacific Opioid-Induced Constipation Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific Opioid-Induced Constipation Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 South America by Region, by Type, and by Application
10.1 South America Opioid-Induced Constipation Sales by Type (2017-2028)
10.2 South America Opioid-Induced Constipation Sales by Application (2017-2028)
10.3 South America Opioid-Induced Constipation Market Size by Country
10.3.1 South America Opioid-Induced Constipation Sales in Volume by Country (2017-2028)
10.3.2 South America Opioid-Induced Constipation Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Opioid-Induced Constipation Sales by Type (2017-2028)
11.2 Middle East & Africa Opioid-Induced Constipation Sales by Application (2017-2028)
11.3 Middle East & Africa Opioid-Induced Constipation Market Size by Country
11.3.1 Middle East & Africa Opioid-Induced Constipation Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa Opioid-Induced Constipation Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 Raw Material and Industry Chain
12.1 Raw Material of Opioid-Induced Constipation and Key Manufacturers
12.2 Manufacturing Costs Percentage of Opioid-Induced Constipation
12.3 Opioid-Induced Constipation Production Process
12.4 Opioid-Induced Constipation Industrial Chain
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Opioid-Induced Constipation Typical Distributors
13.3 Opioid-Induced Constipation Typical Customers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer
List of Tables
Table 1. Global Opioid-Induced Constipation Revenue by Type, (USD Million), 2017 & 2021 & 2028
Table 2. Global Opioid-Induced Constipation Revenue by Application, (USD Million), 2017 & 2021 & 2028
Table 3. Takeda Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 4. Takeda Pharmaceuticals Major Business
Table 5. Takeda Pharmaceuticals Opioid-Induced Constipation Product and Services
Table 6. Takeda Pharmaceuticals Opioid-Induced Constipation Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 7. Bayer Basic Information, Manufacturing Base and Competitors
Table 8. Bayer Major Business
Table 9. Bayer Opioid-Induced Constipation Product and Services
Table 10. Bayer Opioid-Induced Constipation Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 11. Sanofi Basic Information, Manufacturing Base and Competitors
Table 12. Sanofi Major Business
Table 13. Sanofi Opioid-Induced Constipation Product and Services
Table 14. Sanofi Opioid-Induced Constipation Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 15. Mallinckrodt Basic Information, Manufacturing Base and Competitors
Table 16. Mallinckrodt Major Business
Table 17. Mallinckrodt Opioid-Induced Constipation Product and Services
Table 18. Mallinckrodt Opioid-Induced Constipation Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 19. Salix (Bausch Health) Basic Information, Manufacturing Base and Competitors
Table 20. Salix (Bausch Health) Major Business
Table 21. Salix (Bausch Health) Opioid-Induced Constipation Product and Services
Table 22. Salix (Bausch Health) Opioid-Induced Constipation Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 23. AstraZeneca Basic Information, Manufacturing Base and Competitors
Table 24. AstraZeneca Major Business
Table 25. AstraZeneca Opioid-Induced Constipation Product and Services
Table 26. AstraZeneca Opioid-Induced Constipation Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 27. Progenics Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 28. Progenics Pharmaceuticals Major Business
Table 29. Progenics Pharmaceuticals Opioid-Induced Constipation Product and Services
Table 30. Progenics Pharmaceuticals Opioid-Induced Constipation Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 31. Purdue Pharm Basic Information, Manufacturing Base and Competitors
Table 32. Purdue Pharm Major Business
Table 33. Purdue Pharm Opioid-Induced Constipation Product and Services
Table 34. Purdue Pharm Opioid-Induced Constipation Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 35. Nektar Therapeutics Basic Information, Manufacturing Base and Competitors
Table 36. Nektar Therapeutics Major Business
Table 37. Nektar Therapeutics Opioid-Induced Constipation Product and Services
Table 38. Nektar Therapeutics Opioid-Induced Constipation Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 39. Daiichi Sankyo Basic Information, Manufacturing Base and Competitors
Table 40. Daiichi Sankyo Major Business
Table 41. Daiichi Sankyo Opioid-Induced Constipation Product and Services
Table 42. Daiichi Sankyo Opioid-Induced Constipation Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 43. Prestige Basic Information, Manufacturing Base and Competitors
Table 44. Prestige Major Business
Table 45. Prestige Opioid-Induced Constipation Product and Services
Table 46. Prestige Opioid-Induced Constipation Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 47. GSK Basic Information, Manufacturing Base and Competitors
Table 48. GSK Major Business
Table 49. GSK Opioid-Induced Constipation Product and Services
Table 50. GSK Opioid-Induced Constipation Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 51. Shionogi Basic Information, Manufacturing Base and Competitors
Table 52. Shionogi Major Business
Table 53. Shionogi Opioid-Induced Constipation Product and Services
Table 54. Shionogi Opioid-Induced Constipation Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 55. Global Opioid-Induced Constipation Sales by Manufacturer (2019, 2020, 2021, and 2022) & (K Units)
Table 56. Global Opioid-Induced Constipation Revenue by Manufacturer (2019, 2020, 2021, and 2022) & (USD Million)
Table 57. Market Position of Manufacturers in Opioid-Induced Constipation, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2021
Table 58. Global Opioid-Induced Constipation Production Capacity by Company, (K Units): 2020 VS 2021
Table 59. Head Office and Opioid-Induced Constipation Production Site of Key Manufacturer
Table 60. Opioid-Induced Constipation New Entrant and Capacity Expansion Plans
Table 61. Opioid-Induced Constipation Mergers & Acquisitions in the Past Five Years
Table 62. Global Opioid-Induced Constipation Sales by Region (2017-2022) & (K Units)
Table 63. Global Opioid-Induced Constipation Sales by Region (2023-2028) & (K Units)
Table 64. Global Opioid-Induced Constipation Revenue by Region (2017-2022) & (USD Million)
Table 65. Global Opioid-Induced Constipation Revenue by Region (2023-2028) & (USD Million)
Table 66. Global Opioid-Induced Constipation Sales by Type (2017-2022) & (K Units)
Table 67. Global Opioid-Induced Constipation Sales by Type (2023-2028) & (K Units)
Table 68. Global Opioid-Induced Constipation Revenue by Type (2017-2022) & (USD Million)
Table 69. Global Opioid-Induced Constipation Revenue by Type (2023-2028) & (USD Million)
Table 70. Global Opioid-Induced Constipation Price by Type (2017-2022) & (USD/Unit)
Table 71. Global Opioid-Induced Constipation Price by Type (2023-2028) & (USD/Unit)
Table 72. Global Opioid-Induced Constipation Sales by Application (2017-2022) & (K Units)
Table 73. Global Opioid-Induced Constipation Sales by Application (2023-2028) & (K Units)
Table 74. Global Opioid-Induced Constipation Revenue by Application (2017-2022) & (USD Million)
Table 75. Global Opioid-Induced Constipation Revenue by Application (2023-2028) & (USD Million)
Table 76. Global Opioid-Induced Constipation Price by Application (2017-2022) & (USD/Unit)
Table 77. Global Opioid-Induced Constipation Price by Application (2023-2028) & (USD/Unit)
Table 78. North America Opioid-Induced Constipation Sales by Country (2017-2022) & (K Units)
Table 79. North America Opioid-Induced Constipation Sales by Country (2023-2028) & (K Units)
Table 80. North America Opioid-Induced Constipation Revenue by Country (2017-2022) & (USD Million)
Table 81. North America Opioid-Induced Constipation Revenue by Country (2023-2028) & (USD Million)
Table 82. North America Opioid-Induced Constipation Sales by Type (2017-2022) & (K Units)
Table 83. North America Opioid-Induced Constipation Sales by Type (2023-2028) & (K Units)
Table 84. North America Opioid-Induced Constipation Sales by Application (2017-2022) & (K Units)
Table 85. North America Opioid-Induced Constipation Sales by Application (2023-2028) & (K Units)
Table 86. Europe Opioid-Induced Constipation Sales by Country (2017-2022) & (K Units)
Table 87. Europe Opioid-Induced Constipation Sales by Country (2023-2028) & (K Units)
Table 88. Europe Opioid-Induced Constipation Revenue by Country (2017-2022) & (USD Million)
Table 89. Europe Opioid-Induced Constipation Revenue by Country (2023-2028) & (USD Million)
Table 90. Europe Opioid-Induced Constipation Sales by Type (2017-2022) & (K Units)
Table 91. Europe Opioid-Induced Constipation Sales by Type (2023-2028) & (K Units)
Table 92. Europe Opioid-Induced Constipation Sales by Application (2017-2022) & (K Units)
Table 93. Europe Opioid-Induced Constipation Sales by Application (2023-2028) & (K Units)
Table 94. Asia-Pacific Opioid-Induced Constipation Sales by Region (2017-2022) & (K Units)
Table 95. Asia-Pacific Opioid-Induced Constipation Sales by Region (2023-2028) & (K Units)
Table 96. Asia-Pacific Opioid-Induced Constipation Revenue by Region (2017-2022) & (USD Million)
Table 97. Asia-Pacific Opioid-Induced Constipation Revenue by Region (2023-2028) & (USD Million)
Table 98. Asia-Pacific Opioid-Induced Constipation Sales by Type (2017-2022) & (K Units)
Table 99. Asia-Pacific Opioid-Induced Constipation Sales by Type (2023-2028) & (K Units)
Table 100. Asia-Pacific Opioid-Induced Constipation Sales by Application (2017-2022) & (K Units)
Table 101. Asia-Pacific Opioid-Induced Constipation Sales by Application (2023-2028) & (K Units)
Table 102. South America Opioid-Induced Constipation Sales by Country (2017-2022) & (K Units)
Table 103. South America Opioid-Induced Constipation Sales by Country (2023-2028) & (K Units)
Table 104. South America Opioid-Induced Constipation Revenue by Country (2017-2022) & (USD Million)
Table 105. South America Opioid-Induced Constipation Revenue by Country (2023-2028) & (USD Million)
Table 106. South America Opioid-Induced Constipation Sales by Type (2017-2022) & (K Units)
Table 107. South America Opioid-Induced Constipation Sales by Type (2023-2028) & (K Units)
Table 108. South America Opioid-Induced Constipation Sales by Application (2017-2022) & (K Units)
Table 109. South America Opioid-Induced Constipation Sales by Application (2023-2028) & (K Units)
Table 110. Middle East & Africa Opioid-Induced Constipation Sales by Region (2017-2022) & (K Units)
Table 111. Middle East & Africa Opioid-Induced Constipation Sales by Region (2023-2028) & (K Units)
Table 112. Middle East & Africa Opioid-Induced Constipation Revenue by Region (2017-2022) & (USD Million)
Table 113. Middle East & Africa Opioid-Induced Constipation Revenue by Region (2023-2028) & (USD Million)
Table 114. Middle East & Africa Opioid-Induced Constipation Sales by Type (2017-2022) & (K Units)
Table 115. Middle East & Africa Opioid-Induced Constipation Sales by Type (2023-2028) & (K Units)
Table 116. Middle East & Africa Opioid-Induced Constipation Sales by Application (2017-2022) & (K Units)
Table 117. Middle East & Africa Opioid-Induced Constipation Sales by Application (2023-2028) & (K Units)
Table 118. Opioid-Induced Constipation Raw Material
Table 119. Key Manufacturers of Opioid-Induced Constipation Raw Materials
Table 120. Direct Channel Pros & Cons
Table 121. Indirect Channel Pros & Cons
Table 122. Opioid-Induced Constipation Typical Distributors
Table 123. Opioid-Induced Constipation Typical Customers
List of Figures
Figure 1. Opioid-Induced Constipation Picture
Figure 2. Global Opioid-Induced Constipation Revenue Market Share by Type in 2021
Figure 3. Methylnaltrexone Bromide
Figure 4. Lubiprostone
Figure 5. Naloxegol
Figure 6. Others
Figure 7. Global Opioid-Induced Constipation Revenue Market Share by Application in 2021
Figure 8. Hospital
Figure 9. Pharmacy
Figure 10. Other
Figure 11. Global Opioid-Induced Constipation Revenue, (USD Million) & (K Units): 2017 & 2021 & 2028
Figure 12. Global Opioid-Induced Constipation Revenue and Forecast (2017-2028) & (USD Million)
Figure 13. Global Opioid-Induced Constipation Sales (2017-2028) & (K Units)
Figure 14. Global Opioid-Induced Constipation Price (2017-2028) & (USD/Unit)
Figure 15. Global Opioid-Induced Constipation Production Capacity (2017-2028) & (K Units)
Figure 16. Global Opioid-Induced Constipation Production Capacity by Geographic Region: 2022 VS 2028
Figure 17. Opioid-Induced Constipation Market Drivers
Figure 18. Opioid-Induced Constipation Market Restraints
Figure 19. Opioid-Induced Constipation Market Trends
Figure 20. Global Opioid-Induced Constipation Sales Market Share by Manufacturer in 2021
Figure 21. Global Opioid-Induced Constipation Revenue Market Share by Manufacturer in 2021
Figure 22. Opioid-Induced Constipation Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2021
Figure 23. Top 3 Opioid-Induced Constipation Manufacturer (Revenue) Market Share in 2021
Figure 24. Top 6 Opioid-Induced Constipation Manufacturer (Revenue) Market Share in 2021
Figure 25. Global Opioid-Induced Constipation Sales Market Share by Region (2017-2028)
Figure 26. Global Opioid-Induced Constipation Revenue Market Share by Region (2017-2028)
Figure 27. North America Opioid-Induced Constipation Revenue (2017-2028) & (USD Million)
Figure 28. Europe Opioid-Induced Constipation Revenue (2017-2028) & (USD Million)
Figure 29. Asia-Pacific Opioid-Induced Constipation Revenue (2017-2028) & (USD Million)
Figure 30. South America Opioid-Induced Constipation Revenue (2017-2028) & (USD Million)
Figure 31. Middle East & Africa Opioid-Induced Constipation Revenue (2017-2028) & (USD Million)
Figure 32. Global Opioid-Induced Constipation Sales Market Share by Type (2017-2028)
Figure 33. Global Opioid-Induced Constipation Revenue Market Share by Type (2017-2028)
Figure 34. Global Opioid-Induced Constipation Price by Type (2017-2028) & (USD/Unit)
Figure 35. Global Opioid-Induced Constipation Sales Market Share by Application (2017-2028)
Figure 36. Global Opioid-Induced Constipation Revenue Market Share by Application (2017-2028)
Figure 37. Global Opioid-Induced Constipation Price by Application (2017-2028) & (USD/Unit)
Figure 38. North America Opioid-Induced Constipation Sales Market Share by Type (2017-2028)
Figure 39. North America Opioid-Induced Constipation Sales Market Share by Application (2017-2028)
Figure 40. North America Opioid-Induced Constipation Sales Market Share by Country (2017-2028)
Figure 41. North America Opioid-Induced Constipation Revenue Market Share by Country (2017-2028)
Figure 42. United States Opioid-Induced Constipation Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 43. Canada Opioid-Induced Constipation Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 44. Mexico Opioid-Induced Constipation Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 45. Europe Opioid-Induced Constipation Sales Market Share by Type (2017-2028)
Figure 46. Europe Opioid-Induced Constipation Sales Market Share by Application (2017-2028)
Figure 47. Europe Opioid-Induced Constipation Sales Market Share by Country (2017-2028)
Figure 48. Europe Opioid-Induced Constipation Revenue Market Share by Country (2017-2028)
Figure 49. Germany Opioid-Induced Constipation Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 50. France Opioid-Induced Constipation Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 51. United Kingdom Opioid-Induced Constipation Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 52. Russia Opioid-Induced Constipation Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 53. Italy Opioid-Induced Constipation Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 54. Asia-Pacific Opioid-Induced Constipation Sales Market Share by Region (2017-2028)
Figure 55. Asia-Pacific Opioid-Induced Constipation Sales Market Share by Application (2017-2028)
Figure 56. Asia-Pacific Opioid-Induced Constipation Sales Market Share by Region (2017-2028)
Figure 57. Asia-Pacific Opioid-Induced Constipation Revenue Market Share by Region (2017-2028)
Figure 58. China Opioid-Induced Constipation Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 59. Japan Opioid-Induced Constipation Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 60. Korea Opioid-Induced Constipation Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. India Opioid-Induced Constipation Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 62. Southeast Asia Opioid-Induced Constipation Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 63. Australia Opioid-Induced Constipation Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 64. South America Opioid-Induced Constipation Sales Market Share by Type (2017-2028)
Figure 65. South America Opioid-Induced Constipation Sales Market Share by Application (2017-2028)
Figure 66. South America Opioid-Induced Constipation Sales Market Share by Country (2017-2028)
Figure 67. South America Opioid-Induced Constipation Revenue Market Share by Country (2017-2028)
Figure 68. Brazil Opioid-Induced Constipation Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 69. Argentina Opioid-Induced Constipation Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 70. Middle East & Africa Opioid-Induced Constipation Sales Market Share by Type (2017-2028)
Figure 71. Middle East & Africa Opioid-Induced Constipation Sales Market Share by Application (2017-2028)
Figure 72. Middle East & Africa Opioid-Induced Constipation Sales Market Share by Region (2017-2028)
Figure 73. Middle East & Africa Opioid-Induced Constipation Revenue Market Share by Region (2017-2028)
Figure 74. Turkey Opioid-Induced Constipation Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 75. Egypt Opioid-Induced Constipation Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 76. Saudi Arabia Opioid-Induced Constipation Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 77. South Africa Opioid-Induced Constipation Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 78. Manufacturing Cost Structure Analysis of Opioid-Induced Constipation in 2021
Figure 79. Manufacturing Process Analysis of Opioid-Induced Constipation
Figure 80. Opioid-Induced Constipation Industrial Chain
Figure 81. Sales Channel: Direct Channel vs Indirect Channel
Figure 82. Methodology
Figure 83. Research Process and Data Source
Please feel free to write an email to us or to use our electronic ticketing system.
